BAKER BROS. ADVISORS LP Q2 2020 Filing
Filed August 14, 2020
Portfolio Value
$22.7B
Holdings
114
Report Date
Q2 2020
Filing Type
13F-HR
All Holdings (114 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 101 | CPRXCatalyst Pharmaceuticals, Inc. | 500,000 | $2.3B | 10.19% | |
| 102 | —Molecular Templates, Inc. | 158,217 | $2.2B | 9.62% | |
| 103 | OYSTOyster Point Pharma, Inc. | 71,428 | $2.1B | 9.10% | |
| 104 | LPTXEURLeap Therapeutics, Inc. | 978,454 | $2.0B | 9.02% | |
| 105 | —Bellicum Pharmaceuticals, Inc. | 249,123 | $1.9B | 8.16% | |
| 106 | MTNBEURMatinas BioPharma Holdings, Inc. | 2,096,375 | $1.6B | 7.15% | |
| 107 | GLMDGalmed Pharmaceuticals Ltd. | 215,594 | $1.0B | 4.55% | |
| 108 | —Affimed N.V. | 200,000 | $923.0M | 4.07% | |
| 109 | INFIQInfinity Pharmaceuticals, Inc. | 580,400 | $525.0M | 2.32% | |
| 110 | TPIVDEURMarker Therapeutics, Inc. | 240,505 | $498.0M | 2.20% | |
| 111 | —Adamas Pharmaceuticals, Inc. | 172,630 | $442.0M | 1.95% | |
| 112 | GNFTYGenfit SA | 28,396 | $156.0M | 0.69% | |
| 113 | —Sunesis Pharmaceuticals, Inc. | 556,665 | $147.0M | 0.65% | |
| 114 | REPLReplimune Group, Inc. | 5,141 | $128.0M | 0.56% |
PreviousPage 2 of 2